
Moderna and BioNTech yesterday announced promising findings for their phase 1/2 trial of an mRNA vaccine that targets both COVID and flu.
Scientists tested different combo vaccine candidates in healthy adults ages 18 to 64 against a licensed flu vaccine and the companies' earlier bivalent (two-strain) COVID vaccine, with both vaccines given at the same visit. Lead formulations of the combo vaccines prompted robust immune responses against influenza A, influenza B, and SARS-CoV-2, the virus that causes COVID-19.
The safety results for the combo vaccines were similar to the vaccine against COVID.
Based on the findings, the companies said they would advance the lead formulations to a phase 3 trial in the months ahead. The Food and Drug Administration (FDA) has given the company fast-track designation for the new vaccine.
Annaliesa Anderson, PhD, Pfizer’s senior vice president and head of vaccine development, said in a statement that the companies are encouraged by the early trial results, which will appear in a peer-reviewed journal soon. “This vaccine has the potential to lessen the impact of two respiratory diseases with a single injection and may simplify immunization practices for providers, patients, and healthcare systems all over the world,” she said.
Earlier this month, Moderna reported promising findings from an early clinical trial of its mRNA combo vaccine against flu and COVID.